Intravenous diltiazem and CYP3A-mediated metabolism

British Journal of Clinical Pharmacology

Volumn 50, Issue 3, 2000, Pages 273-276

  Masica, A L ^a   Azie, N E ^a   Brater, D C ^a   Hall, S D ^a   Jones, D R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium channel blockers; CYP3A; Diltiazem; Drug interactions; Lovastatin

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 3A; DILTIAZEM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; FIRST PASS EFFECT; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CARDIOVASCULAR AGENTS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DILTIAZEM; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; LOVASTATIN; MALE; OXIDOREDUCTASES, N-DEMETHYLATING;

EID: 0033818219     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00249.x     Document Type: Article

References (23)

1. Treatment of supraventricular tachyarrythmias with intravenous calcium channel blockers: Are subtler differences worth the cost?
2. Re-examining the clinical safety and roles of calcium antagonists in cardiovascular medicine
3. Dilemmas in the acute pharmacologic treatment of uncontrolled atrial fibrillation
4. Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil
5. Diltiazem treatment impairs hepatic drug oxidation. Studies of antipyrine
6. Dose of midazolam should be reduced during diltiazem and verapamil treatments
7. Diltiazem inhibition of CYP3A activity is due to metabolite intermediate complex formation
8. Prolongation of the QT interval related to diltiazem-cisapride interaction
9. Pharmacokinetic interaction between cyclosporin and diltiazem
10. Diltiazem enhances the effects of triazolam by inhibiting its metabolism
11. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting
12. Acute hemodynamic and electrophysiologic effects and safety of high-dose intravenous diltiazem in patients receiving metoprolol
13. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
14. Pharmacokinetic interaction between propranolol and HMG-CoA reductase inhibitor pravstatin and lovastatin
15. Effect of food on pravastatin pharmacokinetics and pharmacodynamics
16. The interaction of diltiazem with lovastatin and pravastatin
17. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule for the calculation of the area under the plasma concentration time curve
18. Identification of glucocorticoid inducible cytochromes p450 in the intestinal mucosa of rats and man
19. Identification of P450IIIA4 (CYP3A4) in human small bowel enterocytes
20. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
21. First-pass metabolism of midazolam by the human intestine
22. Steady state plasma concentrations of diltiazem and metabolites in patients and healthy volunteers